aclacinomycin has been researched along with arsenic trioxide in 1 studies
| Studies (aclacinomycin) | Trials (aclacinomycin) | Recent Studies (post-2010) (aclacinomycin) | Studies (arsenic trioxide) | Trials (arsenic trioxide) | Recent Studies (post-2010) (arsenic trioxide) |
|---|---|---|---|---|---|
| 168 | 8 | 21 | 3,119 | 160 | 1,507 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R | 1 |
1 other study(ies) available for aclacinomycin and arsenic trioxide
| Article | Year |
|---|---|
Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides | 2015 |